The global oncolytic virus therapy market is anticipated to grow with a CAGR of 27.07 % over the forecast period, i.e., 2023 - 2035. Factors such as the increasing prevalence of cancer cases worldwide, followed by the increasing healthcare expenditure and rising investment in cancer research & development are projected to drive the growth of the market in the coming years. Additionally, the increase in clinical trial and approval of new virus therapies are also expected to boost the market growth. The market is estimated to garner a revenue of about USD 1,150 million by the end of 2035, up from a revenue of about USD 85 million in the year 2022.
The global oncolytic virus therapy market is segmented into numerous segments, which include segmentation by therapy type, virus type, indication, demography, end-user, and by region. By therapy type, the market is segmented into HSV-based, adenovirus-based, reovirus, poxviruses, NDV (Newcastle disease virus), and others. By the end of 2035, the HSV-based oncolytic virus therapy segment is anticipated to garner the largest revenue of close to USD 375 Million. HSV helps in expressing immune evasion genes for instance ICP34.5, ICPo, US3, which are focused in inducing and activating host responses to evade the immune system and establish effective long-term latent infection. However, after various research in immunotherapy, it has been observed that treatment of melanoma via herpes simplex virus can address the challenge of the host’s innate antiviral defense mechanism by redirecting these immune cells to attack tumor cells instead via arming the HSV-based oncolytic virus. This has resulted in HSV type-1 in gaining maximum attention owing to the growth of the market’s segment.
On the basis of region, the global oncolytic virus therapy market is segmented into North America, Europe, Asia Pacific, and Rest of the World. The market in North America, amongst the market in all the other regions, is anticipated to garner the largest revenue of nearly USD 535 Million by the end of 2035. Moreover, in the year 2022, the market in the region generated a revenue of over USD 30 Million. An increasing demand for targeted therapies among the people, and the rising cancer cases in the country are anticipated to create a surge in demand for oncolytic virus therapies in the forthcoming years. Further, the country's improved research infrastructure and increasing investment in R&D in the healthcare industry alongside the government's initiatives are also some of the essential driving factors for market development over the forecast period.
Some of the prominent industry leaders in the global oncolytic virus therapy market that are included in our report are Amgen Inc., Shanghai Sunway Biotech Co., Ltd., Oncolys BioPharma Inc., TILT Biotherapeutics Ltd., Oncorus, Inc., Takara Bio Inc., Vyriad, Transgene sa, Lokon Pharma AB, Pfizer Inc., Rigvir Group, Shenzhen Sibiono GeneTech, Oncolytics Biotech Inc, Daiichi Sankyo, Kissei Pharmaceutical Co., Ltd., Boehringer Ingelheim, and others.
The global oncolytic virus therapy market is segmented into numerous segments, which include segmentation by therapy type, virus type, indication, demography, end-user, and by region. By therapy type, the market is segmented into HSV-based, adenovirus-based, reovirus, poxviruses, NDV (Newcastle disease virus), and others. By the end of 2035, the HSV-based oncolytic virus therapy segment is anticipated to garner the largest revenue of close to USD 375 Million. HSV helps in expressing immune evasion genes for instance ICP34.5, ICPo, US3, which are focused in inducing and activating host responses to evade the immune system and establish effective long-term latent infection. However, after various research in immunotherapy, it has been observed that treatment of melanoma via herpes simplex virus can address the challenge of the host’s innate antiviral defense mechanism by redirecting these immune cells to attack tumor cells instead via arming the HSV-based oncolytic virus. This has resulted in HSV type-1 in gaining maximum attention owing to the growth of the market’s segment.
On the basis of region, the global oncolytic virus therapy market is segmented into North America, Europe, Asia Pacific, and Rest of the World. The market in North America, amongst the market in all the other regions, is anticipated to garner the largest revenue of nearly USD 535 Million by the end of 2035. Moreover, in the year 2022, the market in the region generated a revenue of over USD 30 Million. An increasing demand for targeted therapies among the people, and the rising cancer cases in the country are anticipated to create a surge in demand for oncolytic virus therapies in the forthcoming years. Further, the country's improved research infrastructure and increasing investment in R&D in the healthcare industry alongside the government's initiatives are also some of the essential driving factors for market development over the forecast period.
Some of the prominent industry leaders in the global oncolytic virus therapy market that are included in our report are Amgen Inc., Shanghai Sunway Biotech Co., Ltd., Oncolys BioPharma Inc., TILT Biotherapeutics Ltd., Oncorus, Inc., Takara Bio Inc., Vyriad, Transgene sa, Lokon Pharma AB, Pfizer Inc., Rigvir Group, Shenzhen Sibiono GeneTech, Oncolytics Biotech Inc, Daiichi Sankyo, Kissei Pharmaceutical Co., Ltd., Boehringer Ingelheim, and others.
Table of Contents
1. An Outline of the Oncolytic Virus Therapy Market
3. Research Methodology
5. Forces of the Market Constituents
6. Key Market Opportunities for Business Growth
8. Government Regulation: How They Would Aid Business?
10. Global Economic Outlook: Challenges for Global Recovery and Market
11. Impact of COVID-19 on Global Oncolytic Virus Therapy Market
13. Oncolytic Virus Platforms Under Evaluation
16. Competitive Landscape
17. Global Oncolytic Virus Therapy Market Outlook & Projections, Opportunity Assessment, 2022 to 2035
18. North America Oncolytic Virus Therapy Market Outlook & Projections, Opportunity Assessment, 2022 to 2035
19. Asia Pacific Oncolytic Virus Therapy Market Outlook & Projections, Opportunity Assessment, 2022 to 2035
20. Europe Oncolytic Virus Therapy Market Outlook & Projections, Opportunity Assessment, 2022 to 2035
21. Rest of World Oncolytic Virus Therapy Market Outlook & Projections, Opportunity Assessment, 2022 to 2035
Companies Mentioned
- Amgen Inc.
- Shanghai Sunway Biotech Co. Ltd.
- Oncolys BioPharma Inc.
- TILT Biotherapeutics Ltd.
- Oncorus Inc.
- Takara Bio Inc.
- Vyriad
- Transgene sa
- Lokon Pharma AB
- Pfizer Inc.
- Rigvir Group
- Shenzhen Sibiono GeneTech
- Oncolytics Biotech Inc
- Daiichi Sankyo
- Kissei Pharmaceutical Co. Ltd.
- Boehringer Ingelheim
